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Abstract  
 
Under mechanical ventilation with high-inspired oxygen concentration, diffuse 
alveolar damage (DAD) was found to take place in some patients. To clarify the 
molecular pathophysiology of this condition we investigated the time course of gene 
expression changes induced by hyperoxia exposure in mouse lung using real-time 
quantitative polymerase chain reaction (real-time qPCR). Our results normalized by 
glyceraldehyde 3-phosphate dehydrogenase showed that mRNA levels of cysteine rich 
protein 61 (CYR61) and connective tissue growth factor (CTGF) were significantly 
up-regulated, while those of surfactant-associated protein C (SFTPC), cytochrome 
P450, 2F2 (CYP2F2), Claudin 1, (CLDN1), membrane-associated zonula occludens 
protein-1 (ZO-1), lysozyme (LYZS), and P lysozyme structural (LZP-S) were 
significantly down-regulated. Increasing level of mRNAs, each encoding CYR61 and 
CTGF, suggests a serious risk of fibrosing alveolitis. Decrease in levels of mRNAs for 
SFTPC, CYP2F2, CLDN1, ZO-1, LYZS, and LZP-S suggests alveolar dysfunction 
and disruption of the immune system. Moreover we confirmed apoptotic conditions, 
such as significant up-regulations of mRNA levels in Myc and Galectin-3. Hyperoxic 
condition probably yielded reactive oxygen species (ROS), which resulted in a 
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malignant cycle of ROS production by Myc overexpression.     
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Introduction 
 
Mechanical ventilation with high-inspired oxygen concentration is often used in 
care practices for critically ill patients after injury from wound or physical agents. 
Hyperoxia is a known cause of diffuse alveolar damage (DAD) [1], and it is sometimes 
identified upon judicial autopsy. For example, we have experienced cases of burn or 
misuse of respirator equipment, in which DAD was induced due to the association 
between prolonged use of highly concentrated oxygen and clinical disorders, that is, 
hypovolemic shock or bacterial pneumonia [2], respectively. We have posited toxic side 
effects of hyperoxia exposure in medicolegal expert opinions on these cases, however, 
we have required more objective evidence demonstrating the pathogenesis of DAD. 
Hyperoxia-exposure induced retinopathy of premature baby [3] has been previously 
taken into the law court in Japan. Forensically, we should check the toxic side effects of 
prolonged use of highly concentrated oxygen, in lung, too. We think that to clarify the 
molecular pathophysiology of hyperoxia-exposure induced lung injury is novel duty of 
our forensic pathologist as well as anesthesiologist. 
Apart from hyperoxia exposure and mechanical ventilation [4], DAD could be 
caused by various etiology, including paraquat poisoning [5, 6], idiopathic causes [7, 
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8], and non-thoracic trauma [9]. 
Histopathologically, DAD is characterized by the influx of protein-rich edema 
fluid into the air spaces as a consequence of increased permeability of the 
alveolar-capillary barrier [10]. Type I alveolar cells are easily injured, whereas type II 
alveolar cells appear to be more resistant in DAD. It is also well known that injury of 
vascular endothelial cell plays an important role in alveolar damage. 
DAD is a disease which has a high mortality rate and leads to fibrosing alveolitis 
with persistent hypoxemia in serious cases. Improvement in the treatment of patients 
afflicted with it may have contributed to the recent decline in the mortality rate, 
however, the future therapeutic approach hopes to diminish inflammation of the 
alveolar vascular endothelium in the early stage, and to enhance the resolution of 
pulmonary edema [11].  
Mice exposed to 90-95% oxygen concentration die after 4 or 5 days with DAD [12]. 
Now novel transcript profiling technology including cDNA microarray and real-time 
qPCR allows the accurate measurement of changes in gene expression [13]. Therefore 
we examined the time course of gene expression changes using it. To date, no studies 
have been performed with regard to a comprehensive survey of gene expressions in 
DAD induced by hyperoxia exposure.  
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Materials and methods 
 
Animals and hyperoxia exposure 
 
Eight-week-old mice (C57BL/6J, Charles River Japan, Inc.; NINOX Labo Supply 
Inc., Ishikawa, Japan) were purchased and acclimatized to a 12-h light / 12-h dark 
cycle starting at 8:00 and 20:00, respectively. Food and water were available ad 
libitum. 
In the first experiment, we carried out cDNA microarray analysis. 8 male mice 
weighing 22-25g were randomly divided into two groups as follows: 1) 4 mice for 
control group were bred in atmospheric oxygen; 2) another 4 mice as the hyperoxia 
exposure group were bred in a metallic chamber for 2 days, into which oxygen, which 
was supplied from 100% oxygen concentration bomb, flowed at a rate of 0.8 liter / min. 
The oximeter (COSMOS XO-2000, New Cosmos Electric Co., Ltd, Japan) in the 
chamber indicated 90-95% oxygen concentration.  
In the second and third experiment, we carried out real-time qPCR analysis. 16 
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male mice weighing 22-25g were randomly divided into 4 groups as follows: 1) 4 mice 
for control group were bred in atmospheric oxygen; 2) another 12 mice as the 
hyperoxia exposure group were bred in the metallic chamber for 1 day, 2 days, and 3 
days, respectively.   
At the end of these experiments, the mice were anesthetized with an intraperitoneal 
injection of Pentobarbital Sodium (75mg/kg). Heparinized physiological phosphate 
saline buffer was infused into the left ventricle and blood was bled through the incised 
right atrium. 
These animal experiments were approved by the Toyama Animal Care and Use 
Committee in University of Toyama (Toyama, Japan). 
 
Histopathological analysis 
 
The lung specimens were fixed in 10 % formaldehyde buffered with PBS (pH 7.2) 
and then embedded with paraffin. 4 μm tissue sections were prepared for 
Hematoxylin-Eosin stain or immunohistochemical staining.  
The tissue sections were immunostained by the peroxidase method (EnVision 
System, DAKO Inc., Carpinteria, California) to evaluate the localization and degree of 
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reactivity for a mouse monoclonal antibody against thyroid transcription factor-1 
(TTF-1) (DAKO Inc., California; dilution 1 : 100) [14], nitric oxide synthase 2 (NOS2) 
(Santa Cruz biotechnology Inc., California; dilution 1 : 500) , matrix metalloproteinase 
2 (MMP2) (Santa Cruz biotechnology Inc., California; dilution 1 : 500), and Galectin-3 
(Cedarlane Inc., Canada; dilution 1 : 250), respectively. Briefly, after deparaffinization 
the tissue sections were treated for antigen retrieval with tris buffer solution (TRS) in a 
wet chamber using microwaves, three times for 5min each [15, 16]. The sections were 
allowed to cool at room temperature for 30min. The sections were washed in TRS and 
sequentially treated with 3% H2O2 for 15min to exhaust endogenous peroxidase. After 
washing with TRS and blocking with 5% normal horse serum for 30min, the sections 
were incubated with a primary antibody in a wet chamber using microwaves for 10min. 
After three washes with TRS, the peroxidase-labeled polymer from the EnVision 
System kit was applied for 10min in a wet chamber using microwaves. After washing 
in TRS, the color was developed with the Vector VIP substrate kit (Vector Laboratories, 
Burlingame, California), and the tissue sections were counterstained with Mayer’s 
Hematoxylin.  
For a negative control, each monoclonal antibody was replaced with normal mouse 
serum (DAKO Inc., Carpinteria, California). 
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 Measurement of inflammatory cells expressing Galectin-3 
 
The number of alveolar macrophages and other inflammatory cells expressing 
Galectin-3 was enumerated on 10-randomly chosen visual fields (magnification, ×
200) of the tissue sections stained with it. The statistical test of the average number of 
10-microscopic fields was performed in SPSSTM (SPSS Japan Inc., Tokyo, Japan). 
 
Separation of total RNA and mRNA  
 
Total RNA was extracted from the lung using an RNeasy Protect Mini Kit (Qiagen 
Inc., Tokyo, Japan). It should be noted that total RNA samples were treated with 
RNase-Free DNase (Qiagen Inc., Tokyo, Japan) for 30min at room temperature.  
mRNA was extracted from the DNase-treated sample using an GenEluteTM mRNA 
Miniprep Kit (Sigma Inc., Saint Louis, USA) before cDNA microarray analysis was 
performed. 
 
cDNA microarray analysis 
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 cDNA microarray analysis was performed by IntelliGeneTM Mouse CHIP (Code No. 
X2021, Takara Shuzo Inc., Tokyo, Japan), which were spotted with 4277 cDNA 
fragments of mouse known genes. cDNA probes were prepared by reverse transcriptase 
reaction (RT reaction) (Omniscript Reverse Transcriptase, Qiagen Inc., Tokyo, Japan) 
with Cy3-dUTP (Amersham Pharmacia Biotech Inc., Tokyo, Japan) or Cy5-dUTP 
(Amersham Pharmacia Biotech Inc., Tokyo, Japan) and mRNA from the lung of both 
the control and hyperoxia exposure group, respectively, using an RNA Fluorescence 
Labeling Core Kit (Takara Shuzo Inc., Tokyo, Japan). In the first experiment, the 
control group was labeled with Cy3 and the hyperoxia exposure group was labeled with 
Cy5. In the second experiment, the control group was labeled with Cy5 and the 
hyperoxia exposure group was labeled with Cy3. Identical results were essentially 
expected. After treatment with RNase H, cDNA probes were purified by gel filtration. 
Hybridization and washing of the microarray were carried out according to the 
manufacturer’s instructions. In brief, cDNA probe solutions containing both Cy3- and 
Cy5-labeled cDNA probes were applied to the microarrays, and then the microarrays 
were covered with a spaced glass cover slip (Takara Shuzo Inc., Tokyo, Japan) and 
placed in a humidified chamber at 65˚C for 16h. Following this, the microarrays were 
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sequentially washed in 2× SSC (150mM NaCl and 15mM sodium citrate) containing 
0.2% SDS for 5min twice at 55˚C, in 2× SSC containing 0.2% SDS for 5min once at 
65˚C, and in 0.05× SSC for 1min once at room temperature. The microarrays were 
scanned in both Cy3 and Cy5 channels with a ScanArray Lite (Packard BioChip 
Technologies, Billerica, MA, USA). QuantArray software (Packard BioChip 
Technologies, USA) was used for image analysis. Genes were considered to be 
positively-expressed if the signal / background ratio was >3.0. The average of Cy3 and 
Cy5 signals for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (8 spots each) 
gave a ratio that was used to balance or normalize the signals.  
 
Pathway analysis  
 
To construct signal transduction pathway of DAD, up- and down- regulated genes 
from cDNA microarray analysis were analyzed using ingenuity pathway analysisTM 
(Ingenuity Systems, Inc., Redwood city, California, USA). 
 
Real-time qPCR assay 
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RT reaction (Omniscript Reverse Transcriptase, Qiagen Inc., Tokyo, Japan) was 
carried out with DNase-treated total RNA and an oligo d(T)16 primer. Real-time qPCR 
was performed according to the manufacturer’s instructions for SYBR Premix Ex TaqTM 
(Takara Shuzo Inc., Tokyo, Japan) using the specific primers listed in Table 1. 
Amplification was performed by one round of pre-denaturation at 95˚C for 10sec, 
step-cycle mode of 40 rounds of denaturation at 95˚C for 10sec, annealing and 
extension at 60˚C for 40sec. All reactions were performed in an Mx3000P (Stratagene 
Inc., La Jolla, USA). Fold change was normalized by the expression level of GAPDH.  
 
Statistical analysis 
 
The means, standard errors of the means (SEMs), and statistical analyses were 
calculated using SPSSTM (SPSS Japan Inc., Tokyo, Japan) in the present study. The 
unpaired Student’s t-test was performed between the control (n = 10 fields, Figs. 1c, e) 
and hyperoxia exposure group (n = 10 fields, Figs. 1d, e) in histopathological analysis, 
conversely done between the control (n = 4 mice, Figs. 2, 3) and hyperoxia exposure 
group (n = 4 mice, Figs, 2, 3) in real-time qPCR assay. P values less than 0.05 were 
regarded as significant.  
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Results  
 
Histopathological findings  
 
Histopathological findings together with Hematoxylin-Eosin stain and 
immunohistochemical staining with Galectin-3 in each group are shown in Fig. 1. 
Histopathological findings depended on examination of the sample tissues from each 
of the lung lobes, and were found to be similar.    
Hematoxylin-Eosin stain showed no significant difference between the control and 
the group of two-days’ hyperoxia exposure (Figs. 1a, b). Immunohistochemical 
staining with TTF-1 antibody highlighted the nucleus of type II alveolar cells and Clara 
cells. It did not enable us to recognize distinct regenerative hyperplasia of type II 
alveolar cell. Immunohistochemical stainings with NOS2 and MMP2 showed no 
marked difference between the control and hyperoxia exposure groups.  
However, immunohistochemical staining with Galectin-3 of the hyperoxia 
exposure group revealed that it was significantly expressed in alveolar macrophages 
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and other inflammatory cells, compared with the control group (Figs. 1c, d, e).  
 
cDNA microarray analysis  
 
In order to assess expression of the genome-wide genes in DAD induced by 
hyperoxia exposure, we carried out cDNA microarray analysis of mouse lung.  
Genes in which the averaged fold change was above 1.5 were listed in Table 2. 
These were 5 genes in 4277 genes analyzed, which were cysteine rich protein 61 
(CYR61), ferritin light chain 1 (FTL1), connective tissue growth factor (CTGF), 
gamma actin, cytoplasmic 1 (Actg1), and solute carrier family 3, member 2 (Slc3a2). 
Whereas the averaged fold changes of 30 genes among those were below 0.67. These 
were hemoglobin, beta adult major and minor chain (Hbb-b1 and Hbb-b2), 
surfactant-associated protein C (SFTPC), P lysozyme structural (LZP-S), lysozyme 
(LYZS), cytochrome P450, 2f2 (CYP2F2), and so on, as listed in Table 3.  
This cDNA microarray doesn’t include Myc, Galectin-3, Occludin (OCLN), 
Claudin 1 and 18 (CLDN1 and CLDN18), and membrane-associated zonula occludens 
protein-1 (ZO-1). 
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Time course of gene expression changes in real-time qPCR assay 
 
We examined the time course of gene expression changes using real-time qPCR.  
Fig. 2 showed the time course of gene expression changes in which the raw data 
were analyzed between the control and hyperoxia exposure group. GAPDH was 
significantly up-regulated when hyperoxia exposure was continued. In 3 days’ exposure, 
Myc, Galectin-3, CYR61, CTGF, and FTL1 were significantly up-regulated, while 
Hbb-b2, SFTPC, CYP2F2, CLDN1, ZO-1, LYZS, and LZP-S were significantly 
down-regulated.  
Fig. 3 showed the time course of gene expression changes in which the data 
normalized by GAPDH were analyzed between the control and hyperoxia exposure 
group. Five genes including Myc, Galectin-3, CYR61, CTGF, and FTL1 were 
significantly up-regulated. Except for Galectin-3 and FTL1, the time courses had 
unidirectional tendencies. On the contrary, ten genes including Hbb-b1, Hbb-b2, 
SFTPC, CYP2F2, OCLN, CLDN 1 and 18, ZO-1, LYZS, and LZP-S were significantly 
down-regulated and mRNA levels decreased more and more when hyperoxia exposure 
was continued. 
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 Discussion 
 
To clarify the molecular pathophysiology of DAD induced by hyperoxia exposure, 
we examined lungs of mice which were bred under high oxygen concentration for 1, 2, 
and 3 days. We used GAPDH to normalize the expression levels of the target mRNAs. 
The GAPDH was significantly up-regulated when hyperoxia exposure was continued 
(Fig. 2). Analysis of raw data (Fig. 2) and analysis of GAPDH-normalized data (Fig. 3) 
showed that twelve genes except for Hbb-b1, OCLN, and CLDN18 were similarly up- 
or down-regulated in the second and third experiment of 3 days’ exposure. The 
biological significance of these three genes requires confirmation by future analysis. 
We posit that other twelve results normalized by GAPDH have a biological significance 
in hyperoxia-induced DAD, because the time courses of expression changes for these 
genes had similar tendencies between the second and third experiment. 
Histopathologically, Hematoxylin-Eosin stain and immunohistochemical staining 
with TTF-1, NOS2, and MMP2 showed no significant difference between the control 
and hyperoxia exposure groups.  
However, immunohistochemical staining with Galectin-3 of the hyperoxia 
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exposure group revealed that it was significantly expressed in alveolar macrophage and 
other inflammatory cells. Moreover, mRNA levels of Galectin-3 and Myc were 
significantly up-regulated in the hyperoxia exposure group. These imply undergoing 
apoptosis because Galectin-3 is an anti-apoptotic lectin that protects macrophages or T 
cells from death triggered by a variety of agents [17], and aberrant expression of Myc 
induces apoptosis [18]. 
Additionally, we assessed expression of the other genes which were selected from 
evidence of cDNA microarray analysis and its pathway analysis or articles on DAD. 
CYR61, CTGF, and FTL1 were significantly up-regulated, while Hbb-b2, SFTPC, 
CYP2F2, CLDN1, ZO-1, LYZS, and LZP-S were significantly down-regulated. The 
time courses of expression changes for these genes had unidirectional tendencies 
except for Galectin-3 and FTL1. 
FTL1 encodes ferritin light chain 1 [19]. The functional molecule made of 24 
identical subunits contains a central cavity, into which up to 4,500 insoluble iron ions 
is deposited. H-rich ferritins (H subunit, molecular weight; 21,000) have been shown 
to accumulate or release iron faster than L-rich ferritins (L subunit, molecular weight; 
19,000). Therefore, a greater proportion of H subunits is observed in erythropoietic 
tissue, and a greater proportion of L subunits is found in iron-storing tissue such as 
 - 19 -
liver [20]. Sharkey et al. reported that initial serum ferritin elevation level correlated 
with the subsequent development of DAD [21]. Our result suggests the hyperfunction 
of reticulo-endothelial system due to process hemorrhaging which results from 
increased permeability of the alveolar-capillary barrier. 
Hbb-b1 and Hbb-b2 exist in the cluster [22]. β-minor globin (Hbb-b2) gene 
expression is preferentially reduced in EKLF (erythroid Kruppel-like factor) knock-out 
mice and expression of the β-minor globin gene is more affected by EKLF deprivation 
than the β-major gene (Hbb-b1) [23]. This phenomenon is partially consistent with our 
observations, in which erythroid transcription factors such as EKLF appear to interact 
with the state of high oxygen concentration. 
CYR61 plays essential roles in embryonic vascular development, while CTGF is 
secreted by vascular endothelial cells and promotes proliferation and differentiation of 
chondrocytes and enhances fibroblast growth factor-induced DNA synthesis. CTGF is 
expressed in advanced atherosclerotic lesions [24] or in renal fibrosis induced by 
hypoxia [25]. Bork proposed to group these genes under the denomination “CCN 
family” for CTGF, Cef10/CYR61, and nov [26]. The significance of the CCN family is 
underscored by the finding that targeted disruptions of CCN1 (CYR61) and CCN2 
(CTGF) both lead to lethality in mice. Both CCN1 and CCN2 promote a broad 
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spectrum of cellular processes, including cell adhesion [27], migration, proliferation, 
and differentiation. Increasing levels of mRNAs each encoding CYR61 and CTGF 
suggest a serious risk for developing fibrosing alveolitis relevant to the inappropriate 
wound healing after DAD. 
SFTPC encodes pulmonary surfactant-associated protein C (SP-C) [28], which 
promotes alveolar stability by lowering the surface tension at the air-liquid interface in 
the peripheral air spaces. Pulmonary surfactant consists of 90 % lipid and 10 % protein 
including four surfactant-associated protein: two hydrophilic carbohydrate-binding 
glycoproteins which are surfactant-associated protein A and D, and two small 
hydrophobic proteins which are surfactant-associated protein B and C. SP-C deficient 
mice develop a severe pulmonary disorder associated with atypical accumulations of 
intracellular lipids in type II alveolar cell, and emphysema [29]. Our result posits a 
serious risk for pulmonary collapse and emphysema. 
CYP2F2 encodes the cytochrome P450 2F2; Naphthalene dehydrogenase, which 
belongs to the cytochromes P450 family and is a group of heme-thiolate 
monooxygenases [30]. This enzyme is involved in an NADPH-dependent electron 
transport pathway. It oxidizes a variety of structurally unrelated compounds, including 
steroids, fatty acids, and xenobiotics. Therefore, it catalyzes the production of a very 
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potentially toxic intermediate that is associated with necrosis of type II alveolar cells 
and Clara cells. A decrease in level of mRNA for CYP2F2 implies a serious risk of 
pulmonary collapse because of loss of production for lung surfactants in these cells. 
Alveolar-capillary barrier, composed of the alveolar epithelia and capillary 
endothelia, creates a selective barrier to water and solute flux between alveolar space 
and capillary. Especially, tight junctions regulate paracellular permeability of epithelia 
and endothelia. Recent reports have suggested that occludin (OCLN) may dimerize, 
forming a binding site for membrane-associated zonula occludens protein-1 (ZO-1), 
and ZO-1 connects occludin and claudins (CLDNs) to the cytoskeleton [31, 32]. These 
molecular weights are 65kDa (OCLN), 22 kDa (CLDN1), 29 kDa (CLDN 18), and 
225 kDa (ZO-1), respectively [33, 34]. Alterations in tight junctions occur the influx 
of protein-rich edema fluid into the air spaces. Decrease in levels of mRNAs for 
CLDN1 and ZO-1 suggests alveolar dysfunction, resulting from formation of hyaline 
membrane and collapsed alveoli.  
And lysozymes (LYZS) encodes the lysozyme C, type M (milk); 
1,4-beta-N-acetylmuramidase C. Mouse has two lysozyme Cs which are type M (milk) 
and type P (intestinal) (LZP-S) [35]. Lysozyme C is capable of hydrolysis of 
1,4-beta-linkages between N-acetylmuramic acid and N-acetyl-D-glucosamine 
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residues in peptidoglycan and between N-acetyl-D-glucosamine residues in 
chitodextrins. In general, this enzyme is present in cytoplasmic granules of the 
polymorphonuclear neutrophils and has primarily a bacteriolytic function in tissues 
and body fluids such as tears and saliva. A decrease in levels of mRNAs for LYZS and 
LZP-S suggests a serious risk for progression of infection because of disruption of the 
immune system. 
Physiologically, reactive oxygen species (ROS) are produced in the electron 
transport system of mitochondria or NADPH oxidase system of phagocytes. ROS play 
a crucial role in DAD induced by hyperoxia exposure and there is growing evidence 
that ROS induce cytokines [36]. A prior oxidative stress, including interleukin-1, can 
confer resistance or tolerance to subsequent oxidative stress [37, 38, 39]. Treatment 
with lisofylline inhibits hyperoxia-induced increase in tumor necrosis factor-alpha, 
interleukin-1β, and interleukin-6 [40]. It is generally accepted that Myc 
overexpression can induce the production of ROS in mitochondria, leading to DNA 
damage and genomic instability such as gene amplification and polyploidy [41]. Our 
result that Myc was significantly up-regulated means that ROS produced by hyperoxia 
exposure induce Myc overexpression, and finally a malignant cycle of ROS 
production starts. ROS cause extreme damage to DNA or other cytoplasmic 
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components, including the plasma membrane or the mitochondrial outer and inner 
membrane. It leads to morphologic changes of pulmonary vascular endothelia or 
alveolar epithelia, causing the influx of protein-rich edema fluid into the air spaces in 
turn. 
In conclusion, the mRNA levels of Myc, Galectin-3, CYR61, CTGF and FTL1 
were significantly up-regulated, while those of Hbb-b2, SFTPC, CYP2F2, CLDN1, 
ZO-1, LYZS, and LZP-S were significantly down-regulated in DAD induced by 
hyperoxia exposure. Up-regulations of CYR61 and CTGF suggest a serious risk for 
fibrosing alveolitis. Down-regulations of SFTPC, CYP2F2, CLDN1, ZO-1, LYZS, and 
LZP-S mean alveolar dysfunction and disruption of the immune system. 
Overexpression of Myc and Galectin-3 implies the onset of apoptosis. Especially, Myc 
overexpression means a malignant cycle of ROS production in lung. Our present 
results regarding changes in gene expressions will provide a novel finding in 
pathogenesis of DAD and open up new avenues for therapeutic intervention. 
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Legends to Figures 
 
Fig. 1 
Hematoxylin-Eosin stain of the control group (a) and the group of two-days’ 
hyperoxia exposure (b), in the lung tissues from mice. It showed no significant 
difference between the control and hyperoxia exposure groups. 
 Immunohistochemical staining with Galectin-3 of the control group (c) and the 
group of two-days’ hyperoxia exposure (d), in the lung tissues from mice. The 
hyperoxia exposure group revealed that it was significantly expressed in alveolar 
macrophages and other inflammatory cells, compared with the control group.  
The number of cells expressing Galectin-3 is enumerated on 10-randomly chosen 
visual fields (magnification, ×200) of the tissue sections stained with Galectin-3 (e). 
Bars show means and error bars show standard errors of the means (SEMs). Unpaired 
Student’s t-test is performed between the control and hyperoxia exposure groups. P 
value was less than 0.001 (***p<0.001). 
 
Fig. 2 
Time course of gene expression changes in DAD induced by hyperoxia exposure. 
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White and black bars show data of the second and third experiment, respectively. The 
raw data are analyzed between the control and hyperoxia exposure group. Each of fold 
changes for hyperoxia exposure groups was divided by averages of those for the control 
groups. Accordingly, fold change indicates 1.0 if data for both the control and 
hyperoxia exposure groups are same. Bars show means and error bars show standard 
errors of the means (SEMs). Unpaired Student’s t-test is performed between the control 
and hyperoxia exposure groups. P values less than 0.05 are regarded as significant: 
*p<0.05, **p<0.01, ***p<0.001. mRNA level for GAPDH is significantly up-regulated 
when hyperoxia exposure is continued. In 3 days’ exposure, Myc, Galectin-3, CYR61, 
CTGF, and FTL1 are significantly up-regulated, while Hbb-b2, SFTPC, CYP2F2, 
CLDN1, ZO-1, LYZS, and LZP-S are significantly down-regulated.  
 
Fig. 3 
Time course of gene expression changes in DAD induced by hyperoxia exposure. 
White and black bars show data of the second and third experiment, respectively, as Fig. 
2. The data normalized by GAPDH are analyzed between the control and hyperoxia 
exposure groups. mRNA levels for five genes including Myc, Galectin-3, CYR61, 
CTGF, and FTL1 are significantly up-regulated. Whereas mRNA levels for ten genes 
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including Hbb-b1, Hbb-b2, SFTPC, CYP2F2, OCLN, CLDN 1 and 18, ZO-1, LYZS, 
and LZP-S are significantly down-regulated. 
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Table 1    Nucleotide sequences of primers for real-time qPCR assay
Gene symbol GenBank accession no. Orientation Nucleotide sequence                               Position, Size of the amplified PCR product
Myc NM_010849 Sense 5'-GAACTTCACCAACAGGAACTATGAC-3' 596-620 145 bp
Antisense 5'-GAATTTCTTCCAGATATCCTCACTG-3' 740-716
Galectin-3 NM_010705 Sense 5'-CAACAGGAGAGTCATTGTGTGTAAC-3' 581-605 118 bp
Antisense 5'-TTCAACCAGGACTTGTATTTTGAAT-3'  698-674
CYR61 NM_010516 Sense 5'-AGACCCTGTGAATATAACTCCAGAA-3'  481-505 300 bp
Antisense 5'-AATTGCGATTAACTCATTGTTTCTC-3' 780-756
CTGF NM_010217 Sense 5'-CCAACTATGATGCGAGCCAACTGCC-3' 790-814 356 bp
Antisense 5'-CCATCGGGGCATTTGAACTCCACTG-3' 1145-1121
FTL1 NM_010240 Sense 5'-CGAATTGGCCGAGGAGAAGCGCGAG-3' 364-388 393 bp
Antisense 5'-TAGTCGTGCTTGAGAGTGAGGCGCT-3'  756-732
Hbb-b1 NM_008220 Sense 5'-GGTACTTTGATAGCTTTGGAGACCT-3' 178-202 102 bp
Antisense 5'-CATCGTTAAAGGCAGTTATCACTTT-3' 279-255
Hbb-b2 NM_016956 Sense 5'-ACTTGCAACTTCAGAAACAGACATC-3' 10-34 171 bp
Antisense 5'-AGGTCTCCAAAGCTATCAAAGTACC-3' 180-156
SFTPC NM_011359 Sense 5'-GCTCCAGGAACCTACTGCTACATCA-3' 373-397 163 bp
Antisense 5'-AAGAATCGGACTCGGAACCAGTATC-3' 535-511
CYP2F2 NM_007817 Sense 5'-GCTGATGACCACACACAACCTGCTC-3' 925-949 355 bp
Antisense 5'-CTGAGGCGTCTTGAACTGGTCCGAG-3' 1279-1255
OCLN NM_008756 Sense 5'-CTGCAGGAGTATAAGAGCTTACAGG-3' 1494-1518 188 bp
Antisense 5'-TGCTTGCAGTAATTCCTCTTACTTT-3' 1681-1657
CLDN1 NM_016674 Sense 5'-CAGTGGAAGATTTACTCCTATGCTG-3' 299-323 300 bp
Antisense 5'-AATTAAAAATATTATGCCCCCAATG-3' 598-574
CLDN18 NM_019815 Sense 5'-CAACTTCAAAGCTGTGTCTTACCAT-3' 688-712 115 bp
Antisense 5'-ATCGTAGATCTTCTTGTTTCTGGTG-3' 802-778
ZO-1 D14340 Sense 5'-GTTGTGTTCCTTAACCCTGACTCTA-3' 2576-2600 138 bp
Antisense 5'-TGTGAAGAGATGGTGATTGTTCTTA-3' 2713-2689
LYZS NM_017372 Sense 5'-GGAATGGAATGGCTGGCTACTATGG-3' 117-141 284 bp
Antisense 5'-TGCTCGAATGCCTTGGGGATCTCTC-3' 400-376
LZP-S NM_013590 Sense 5'-CAGCATGAGAGCAATTATAACACAC-3' 181-205 278 bp
Antisense 5'-ATATACTGGGACAGATCTCGGTTTT-3' 458-434
GAPDH M32599 Sense 5'-GCCATCAACGACCCCTTCAT-3' 134-153 269 bp
Antisense 5'-ATGATGACCCGTTTGGCTCC-3' 402-383
Table 2    Genes up-regulated in mice
Gene name Gene ontology GenBank accession no. Ratio 1 Ratio 2 Mean
cysteine rich protein 61 (Cyr61) growth factor-binding protein, angiogenesis  NM_010516 4.00 3.46 3.73
ferritin light chain 1 (Ftl1) iron ion homeostasis NM_010240 2.66 2.00 2.33
connective tissue growth factor (Ctgf) fibroblast proliferation, angiogenesis NM_010217 2.44 1.89 2.16
actin, gamma, cytoplasmic 1 (Actg1) actin cytoskeleton, sarcomere organization NM_009609 1.48 2.16 1.82
solute carrier family 3, member 2 (Slc3a2) cell-surface antigen NM_008577 1.49 1.75 1.62
Table 3    Genes down-regulated in mice
Gene name Gene ontology GenBank accession no. Ratio 1 Ratio 2 Mean
hemoglobin, beta adult minor chain (Hbb-b2) oxygen and carbon dioxide transport NM_016956 0.3 0.38 0.34
hemoglobin, beta adult major chain (Hbb-b1) oxygen and carbon dioxide transport NM_008220 0.35 0.33 0.34
surfactant-associated protein C (Sftpc) alveolar stability NM_011359 0.41 0.34 0.37
P lysozyme structural (Lzp-s) cell wall catabolism, bacteriolytic function NM_013590 0.51 0.25 0.38
lysozyme (Lyzs) cell wall catabolism, bacteriolytic function NM_017372 0.49 0.32 0.4
cytochrome P450, 2f2 (Cyp2f2) oxydization of naphthalene, electron transport NM_007817 0.46 0.38 0.42
RIKEN cDNA 1810057C19 gene (1810057C19Rik) Unknown NM_026433 0.4 0.47 0.43
stearoyl-Coenzyme A desaturase 1 (Scd1) fatty acid biosynthesis, superoxide metabolism NM_009127 0.54 0.32 0.43
thioether S-methyltransferase (Inmt) sulfur and selenium metabolism NM_009349 0.44 0.48 0.46
RIKEN cDNA 2700055K07 gene (2700055K07Rik ) Unknown NM_026481 0.56 0.36 0.46
myosin, light polypeptide 4 (Myl4) structural constituent of muscle, muscle contraction NM_010858 0.49 0.47 0.48
selenium binding protein 2 (Selenbp2) selenium and acetaminophen binding NM_019414 0.48 0.53 0.51
troponin T2, cardiac (Tnnt2) structural constituent of muscle, muscle contraction NM_011619 0.52 0.53 0.53
ATPase, Ca2+ transporting, cardiac muscle, slow twitch 2 (Atp2a2) contractile function NM_009722 0.45 0.61 0.53
haptoglobin (Hp) hemoglobin binding, acute-phase response NM_017370 0.47 0.59 0.53
sodium/hydrogen exchanger, isoform 3 regulator 2 (Slc9a3r2) transepithelial sodium absorption NM_023055 0.6 0.49 0.54
elongation of very long chain fatty acids -like 1 (Elovl1) elongation of very long chain fatty acids NM_019422 0.58 0.51 0.55
DNA segment, Chr 4 (D4Wsu53e) nucleic acid binding NM_023665 0.56 0.55 0.55
stearoyl-Coenzyme A desaturase 2 (Scd2) fatty acid biosynthesis, superoxide metabolism NM_009128 0.59 0.52 0.55
aquaporin 1 (Aqp1) water transport, integral to plasma membrane NM_007472 0.54 0.6 0.57
carbonic anhydrase 3 (Car3) carbonate dehydratase activity, high concentration in muscle NM_007606 0.6 0.57 0.59
fatty acid binding protein 4, adipocyte (Fabp4) fatty acid binding, cholesterol homeostasis NM_024406 0.64 0.54 0.59
cysteine rich protein 2 (Crip2) hemopoiesis, positive regulation of cell proliferation NM_024223 0.65 0.56 0.6
opioid growth factor receptor (Ogfr) opioid receptor activity, modulation of cell proliferation NM_031373 0.65 0.56 0.6
thyroid hormone responsive SPOT14 homolog (Rattus) (Thrsp) lipogenesis NM_009381 0.65 0.57 0.61
dynein, cytoplasmic, light chain 1 (Dnclc1) protein inhibitor of neuronal NOS, actin filament organizaion NM_019682 0.64 0.6 0.62
receptor (calcitonin) activity modifying protein 2 (Ramp2) G-protein coupled receptor protein signaling pathway NM_019444 0.65 0.63 0.64
transmembrane protein 59 (Tmem59) Unknown NM_029565 0.66 0.63 0.65
forkhead box G1 (Foxg1) forebrain development, ganglia morphogenesis NM_008241 0.65 0.66 0.65
RIKEN cDNA 2410005O16 gene (2410005O16Rik) Unknown NM_025476 0.66 0.67 0.67
